UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: June, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
June 8, 2004
By: /s/ David Skinner
----------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
[LOGO NEUROCHEM] NEUROCHEM INC.
275 Armand-Frappier Blvd
Laval , Quebec, Canada H7V 4A7
- -------------------------------------------------------------------------------
DR. FRANCESCO BELLINI RECEIVES
THE ORDRE NATIONAL DU QUEBEC
MONTREAL, CANADA, JUNE 8, 2004 - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is
pleased to announce that the Premier of Quebec, Mr. Jean Charest, has appointed
Dr. Francesco Bellini, Neurochem's Chairman and CEO, as officer of the Ordre
national du Quebec. The appointment was made in honor of his achievements and
contribution to the development of Quebec in the fields of science, business and
community involvement.
In 1986, Dr. Bellini co-founded BioChem Pharma, one of Canada's most successful
biopharmaceutical companies, responsible for the discovery of 3TC(R), the
world's most prescribed anti-HIV/AIDS medication. He is widely acclaimed as a
pioneer of Quebec's and Canada's biopharmaceutical industry.
During his career, Dr. Bellini has received broad recognition for his
achievements. In 2000, he was named an officer of the Order of Canada. He also
received the highest distinction awarded by the Italian government to a person
for his contribution to Italy, the Onorificenza Di Grande Ufficialle. In 1999,
he was named Great Montrealer from l'Academie des Grands Montrealais. He has
also previously received a Ph.D. Honoris Causa from the following institutions:
University of New Brunswick, University of Ottawa, Concordia University, and
McGill University.
Dr. Bellini is also well known for his community involvement. Among his many
commitments, he is a Director of Montreal's Heart Research Fund, a Governor of
Concordia University, a Governor of the Canadian-Italian Community Foundation, a
Governor of Marie-Clarac Hospital Foundation, a Fellow of the Royal Society for
the Encouragement of Arts, Manufacturers & Commerce, a member of Chemical
Institute of Canada, an Honorary Trustee of the Sir Mortimer B. Davis Jewish
General Hospital Foundation. He is an active philanthropist having widely
supported many universities, hospitals and patient organizations, including
through a major financial contribution for the Life Sciences Building at McGill
University.
Dr. Bellini's business activities are extensive. In addition to his strategic
role at Neurochem Inc., Dr. Bellini is Chairman of Picchio Pharma Inc., a joint
venture established between Dr. Bellini and Power Technology Investment
Corporation; Chairman of Adaltis Inc., an international healthcare company that
develops, manufactures and markets sophisticated laboratory products for the
diagnosis of human diseases; Chairman of Innodia Inc., a company specialized in
the development of innovative treatments for Diabetes; and Chairman of the newly
created ViroChem Pharma Inc., a pharmaceutical antiviral research and
development
organization. He is also a member of the board of directors of
Industrial-Alliance Life Insurance Company and of Molson Inc.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical, unmet medical needs.
Fibrillex(TM), designated as an orphan drug and as a Fast Track Product
candidate, is in a Phase II/III clinical trial for the treatment of Amyloid A
Amyloidosis. Alzhemed(TM) and Cerebril(TM), for the treatment of Alzheimer's
Disease and for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid
Angiopathy, respectively, have both completed a Phase II clinical trial. For
additional information on Neurochem, please visit our website at:
(www.neurochem.com).
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this news release. These statements speak only as of the date made and Neurochem
is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D.
Vice President, Corporate Communications
lhebert@neurochem.com
Tel: (450) 680-4500
Fax: (450) 680-4501